文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

糖皮质激素对流感肺炎患者死亡率影响的系统评价与荟萃分析

The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis.
PubMed 文献 · Crit Care · 2019-03-27
一句话结论在成人流感肺炎患者中,使用糖皮质激素与死亡率升高相关(RR 1.75,95%CI 1.30~2.36,P=0.0002)。

该系统评价与荟萃分析检索了PubMed、Embase、Medline、Cochrane CENTRAL和ISI Web of Science数据库,纳入比较糖皮质激素与安慰剂在成人流感肺炎患者中效果的对照研究。共纳入10项试验、6548例患者,主要终点为死亡率,次要终点为机械通气天数、ICU住院时间和继发感染率。与安慰剂相比,糖皮质激素与更高的死亡率(RR 1.75,95%CI 1.30~2.36,P=0.0002)、更长的ICU住院时间(MD 2.14,95%CI 1.17~3.10,P<0.0001)和更高的继发感染率(RR 1.98,95%CI 1.04~3.78,P=0.04)相关,机械通气天数无显著差异(MD 0.81,95%CI -1.23~2.84,P=0.44)。作者结论为在流感肺炎患者中,糖皮质激素使用与更高死亡率相关。

要点

  • 成人流感肺炎患者使用糖皮质激素与死亡率升高相关:RR 1.75(95%CI 1.30~2.36),P=0.0002。
  • 糖皮质激素组继发感染率更高:RR 1.98(95%CI 1.04~3.78),P=0.04。
  • 糖皮质激素组ICU住院时间更长:MD 2.14天(95%CI 1.17~3.10),P<0.0001。
  • 机械通气天数两组无显著差异:MD 0.81天(95%CI -1.23~2.84),P=0.44。
  • 除ICU住院时间(I2=38%,P=0.21)外,所有结局指标均存在显著异质性。

适用人群与场景

  • 成人流感肺炎患者
  • 比较糖皮质激素与安慰剂的对照研究人群

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析,纳入10项对照研究,共6548例成人流感肺炎患者。
  • 主要终点死亡率:与安慰剂相比,糖皮质激素与更高死亡率相关(RR 1.75,95%CI 1.30~2.36,Z=3.71,P=0.0002)。
  • 次要终点ICU住院时间:糖皮质激素组更长(MD 2.14,95%CI 1.17~3.10,Z=4.35,P<0.0001)。
  • 次要终点继发感染率:糖皮质激素组更高(RR 1.98,95%CI 1.04~3.78,Z=2.08,P=0.04)。
  • 次要终点机械通气天数:两组无显著差异(MD 0.81,95%CI -1.23~2.84,Z=0.78,P=0.44)。
  • 异质性:除ICU住院时间(I2=38%,P=0.21)外,所有结局指标均存在显著异质性。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入10项对照研究。
  • 除ICU住院时间外,所有结局指标均存在显著异质性。

对床旁实践的改变

  • 作者结论:在流感肺炎患者中,糖皮质激素使用与更高死亡率相关。

指南或共识出处

  • PROSPERO注册号:CRD42018112384

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The effect of corticosteroids on clinical outcomes in patients with influenza pneumonia remains controversial. We aimed to further evaluate the influence of corticosteroids on mortality in adult patients with influenza pneumonia by comparing corticosteroid-treated and placebo-treated patients.

METHODS: The PubMed, Embase, Medline, Cochrane Central Register of Controlled Trials (CENTRAL), and Information Sciences Institute (ISI) Web of Science databases were searched for all controlled studies that compared the effects of corticosteroids and placebo in adult patients with influenza pneumonia. The primary outcome was mortality, and the secondary outcomes were mechanical ventilation (MV) days, length of stay in the intensive care unit (ICU LOS), and the rate of secondary infection.

RESULTS: Ten trials involving 6548 patients were pooled in our final analysis. Significant heterogeneity was found in all outcome measures except for ICU LOS (I2 = 38%, P = 0.21). Compared with placebo, corticosteroids were associated with higher mortality (risk ratio [RR] 1.75, 95% confidence interval [CI] 1.30 ~ 2.36, Z = 3.71, P = 0.0002), longer ICU LOS (mean difference [MD] 2.14, 95% CI 1.17 ~ 3.10, Z = 4.35, P < 0.0001), and a higher rate of secondary infection (RR 1.98, 95% CI 1.04 ~ 3.78, Z = 2.08, P = 0.04) but not MV days (MD 0.81, 95% CI - 1.23 ~ 2.84, Z = 0.78, P = 0.44) in patients with influenza pneumonia.

CONCLUSIONS: In patients with influenza pneumonia, corticosteroid use is associated with higher mortality.

TRIAL REGISTRATION: PROSPERO (ID: CRD42018112384 ).

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Ni YN, Chen G, Sun J, et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care. 2019. PMID: 30917856. doi:10.1186/s13054-019-2395-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。